文献速递临床试验与 GCP

痰热清口服液治疗急性支气管炎的有效性与安全性:随机对照试验研究方案

Efficacy and safety of Tanreqing oral liquid in treatment of acute bronchitis: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2022-05-07

本试验为前瞻性、多中心、随机、双盲、平行组、安慰剂对照试验,计划从中国9个研究中心门诊和急诊纳入270例痰热壅肺证急性支气管炎成人患者,随机接受痰热清口服液或安慰剂口服液20 mL每日三次连续7天,主要结局为咳嗽消失率,旨在评估痰热清口服液的有效性与安全性。

要点

  • 痰热清口服液或安慰剂口服液20 mL每日三次连续7天。
  • 主要结局为咳嗽消失率,次要结局包括症状评分变化等。
  • 计划纳入270例痰热壅肺证急性支气管炎成人患者。

核心结论

  • 本试验可能为急性支气管炎患者提供一种替代治疗选择,尤其是门诊和急诊患者。
  • 本试验可能为中药治疗急性支气管炎增加证据。

研究设计与样本

  • 前瞻性、多中心、随机、双盲、平行组、安慰剂对照试验。
  • 计划从中国9个研究中心门诊和急诊纳入270例痰热壅肺证急性支气管炎成人患者。
  • 患者随机接受痰热清口服液或安慰剂口服液,20 mL每日三次连续7天。

主要发现

  • 原文未报告结果。

关键数值与推荐

  • 主要结局为咳嗽消失率。
  • 次要结局包括支气管炎症状评分从基线至治疗后的变化、咳嗽缓解率、咳嗽消失时间、咳嗽缓解时间、单一症状消失率、联合用药、中医证候评分从基线至治疗后的变化及不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 5% of adults have an episode of acute bronchitis each year, accounting for more than 10 million medical visits yearly. The primary goal of treatment is reduction of symptoms. Currently, available medications are questionable in effectiveness and safety and are not recommended for routine use in clinical practice. Although Chinese herbal medicine has been widely used in the management of acute bronchitis in China, evidence-based data is lacking. This trial aims to evaluate the efficacy and safety of Tanreqing oral liquid in the treatment of acute bronchitis with phlegm-heat obstructing lungs syndrome. METHODS/DESIGN: This study is a prospective, multi-center, randomized, double-blinded, parallel-group, placebo-controlled trial. A total of 270 acute bronchitis adult patients with phlegm-heat obstructing lungs syndrome will be enrolled from outpatients and emergency departments at nine study centers across China. All included patients will be randomly allocated to receive Tanreqing oral liquid or placebo oral liquid, 20 mL three times daily for seven consecutive days. The primary outcome will be cough resolution rate. Secondary outcomes will include change of bronchitis symptoms scores from baseline to post-treatment, cough relief rate, time to cough resolution, time to cough relief, resolution rate of a single symptom, combination medicine use, change of traditional Chinese medicine syndrome score from baseline to post-treatment, and adverse events. DISCUSSION: This trial may provide an alternative treatment option for acute bronchitis patients, especially those in outpatients and emergency departments. It may also add evidence to Chinese herbal medicine for treating acute bronchitis. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2000040264 . Registered on 26 November 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Cheng G, She B, Mao B, et al. Efficacy and safety of Tanreqing oral liquid in treatment of acute bronchitis: study protocol for a randomized controlled trial. Trials. 2022. PMID: 35526026. doi:10.1186/s13063-022-06318-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。